The company's will provide Protalix's treatment for Gaucher's disease.
Protalix Biotherapeutics Inc. (AMEX:PLX) and Pfizer Inc. (NYSE: PFE; LSE: PFZ) have signed a $30 million short-term supply agreement in Latin America for Protalix's treatment for Gaucher's disease. The companies did not disclose the name of the country.
In late 2009, Pfizer signed an agreement for the exclusive, worldwide rights to commercialize taliglucerase alfa for the treatment of Gaucher disease, except in Israel.
Protalix's share price rose 1.2% at the opening on the American Stock Exchange today to $7.02, giving a market cap of $562 million.
Published by Globes [online], Israel business news - www.globes-online.com - on August 16, 2010
© Copyright of Globes Publisher Itonut (1983) Ltd. 2010